WHO ICTRP trial
TO ASSESS EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH CIRRHOSIS WITH DIABETES AS…
CTRI/2023/06/054459 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/06/054459 |
|---|---|
| Public title | TO ASSESS EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH CIRRHOSIS WITH DIABETES AS COMPARED TO STANDARD MEDICAL REGIMEN |
| Scientific title | ASSESSMENT OF EFFICACY OF DAPAGLIFLOZIN IN PATIENTS OF LIVER CIRRHOSIS WITH DIABETES MELLITUS AS COMPARED TO STANDARD MEDICAL TREATMENT |
| Primary sponsor | Pt BD Sharma Institute of Medical Science, Rohtak |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: K742- Hepatic fibrosis with hepatic sclerosis |
| Interventions | Intervention1: Dapagliflozin: To be given in 10 mg OD oral route daily once only for at least 6 months Control Intervention1: Insulin with or without metformin: Insulin to be given as long acting or short acting form with or without… |
| Registration date | Jun 27, 2023 |
| Target size | 80 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: